Nasus Pharma names Brendan P. O'Grady CEO, succeeding Dan Teleman

Nasus Pharma Ltd. announced on July 28, 2026 that it has appointed Brendan P. O'Grady as Chief Executive Officer, with the leadership change taking effect July 27, 2026. Mr. O'Grady succeeds Dan Teleman, with the leadership transition effective July 27, 2026.¹

The company said O'Grady will lead the Company's next phase of growth, with an initial focus on unlocking the commercial potential of NS002, advancing the Company's pipeline and business development initiatives, and maximizing the value of its proprietary Nasax intranasal technology platform.¹ Chairman Udi Gilboa said the company is working toward a pivotal trial in the fourth quarter of 2026 and topline data readout the first quarter of 2027.¹

O'Grady brings decades of pharma leadership experience. He spent 21 years at Teva Pharmaceuticals in a variety of commercial roles, rising to CEO of Teva USA and EVP North America Commercial while scaling profitability, growth, and productivity.¹ Most recently, from May 2024 to October 2025, Mr. O'Grady served as Chief Executive Officer of Assertio Holdings, Inc. (Nasdaq: ASRT).¹ Between those roles, he served as Chief Executive Officer of the Global Formulations Business at Glenmark Pharmaceuticals Ltd. from June 2022 to February 2024, and as Chief Growth and Commercial Officer of American Well Corporation from August 2021 to June 2022.¹

On the departure side, the company disclosed that a mutual separation agreement with Mr. Dan Teleman was signed on July 24, 2026, under which he agreed to resign as CEO and from the Board, effective July 22, 2026.¹ The filing stated that Teleman's exit was unconnected to any dispute over how the company is run or managed. Teleman is expected to remain available during a transition period as O'Grady takes over, per his notice terms.

The Board also filled its vacant seat: O'Grady was named to the Board to replace Teleman, with his director term running until the company's next scheduled shareholder meeting in 2028. O'Grady's compensation package was approved by the Board of Directors, and remains subject to the approval of the Company's shareholders.¹ Nasus also posted an updated corporate presentation on its website¹ the same day.